<DOC>
	<DOCNO>NCT02234323</DOCNO>
	<brief_summary>The primary objective study evaluate safety rFVIIIFc ( BIIB031 ) previously untreated participant severe hemophilia A . The secondary objective evaluate efficacy rFVIIIFc prevention treatment bleed episode previously untreated patient ( PUPs ) , evaluate rFVIIIFc consumption prevention treatment bleed episode PUPs , describe experience use rFVIIIFc immune tolerance induction ( ITI ) participants inhibitor .</brief_summary>
	<brief_title>An Open Label Study Determine Safety Efficacy Replacement Factor VIII Protein ( Known rFVIIIFc ) Untreated Males With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Key Ability participant 's legally authorize representative ( e.g . parent legal guardian ) understand purpose risk study provide sign date informed consent authorization use confidential health information accordance national local subject privacy regulation . Weight â‰¥3.5 kg time screening . Severe hemophilia A define &lt; 1 IU/dL ( &lt; 1 % ) endogenous FVIII document medical record test Screening Period Key Any exposure blood component , factor VIII replacement product , include commercially available rFVIIIFc time prior screening . Other coagulation disorder ( ) addition hemophilia A . Any concurrent clinically significant major disease , opinion Investigator , would make participant unsuitable enrollment . Current systemic treatment chemotherapy and/or immunosuppressant drug . Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>prophylaxis treatment</keyword>
	<keyword>Hemophilia A</keyword>
	<keyword>Hemophilia</keyword>
	<keyword>episodic treatment</keyword>
</DOC>